Edgewise Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
EWTX$48.74+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(In thousands, except share data)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · Common Stock · · Additional · · Other Comprehensive · · Accumulated · · · | |||||||||||||||||
| · Shares · Amount · Paid-In Capital · Loss · Deficit · Total | |||||||||||||||||
| Balance as of December 31, 2023 | 70,453,342 | | $7 | | $563,487 | | $99 | | $(244,763) | | $318,830 | ||||||
| Issuance of common stock, net of offering costs | | 22,450,206 | | | 2 | | | 238,797 | | | — | | | — | | | 238,799 |
| Exercise of stock options | 380,980 | | — | | 1,926 | | | — | | — | | 1,926 | |||||
| Stock-based compensation | — | | — | | 4,871 | | | — | | — | | 4,871 | |||||
| Other comprehensive loss | | — | | — | | — | | | (960) | | — | | (960) | ||||
| Net loss | | — | | — | | — | | | — | | (28,525) | | (28,525) | ||||
| Balance as of March 31, 2024 | 93,284,528 | | $9 | | $809,081 | | $(861) | | $(273,288) | | $534,941 | ||||||
| Exercise of stock options and vesting of restricted stock | | 283,039 | | | — | | | 1,577 | | | — | | | — | | | 1,577 |
| Purchase of common stock under Employee Stock Purchase Plan | | 75,774 | | | — | | | 422 | | | — | | | — | | | 422 |
| Stock-based compensation | | — | | | — | | | 5,224 | | | — | | | — | | | 5,224 |
| Other comprehensive loss | | — | | | — | | | — | | | (193) | | | — | | | (193) |
| Net loss | | — | | | — | | | — | | | — | | | (31,497) | | | (31,497) |
| Balance as of June 30, 2024 | | 93,643,341 | | $9 | | $816,304 | | $(1,054) | | $(304,785) | | $510,474 | |||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · · · · | |||||||||||||||||
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · Common Stock · · Additional · · Other Comprehensive · · Accumulated · · · | |||||||||||||||||
| · Shares · Amount · Paid-In Capital · Income · Deficit · Total | |||||||||||||||||
| Balance as of December 31, 2024 | | 94,838,466 | | $9 | | $837,363 | | $420 | | $(378,576) | | $459,216 | |||||
| Exercise of stock options | 367,217 | | — | | 2,261 | | | — | | — | | 2,261 | |||||
| Stock-based compensation | — | | — | | 9,059 | | | — | | — | | 9,059 | |||||
| Other comprehensive loss | — | | — | | — | | | (19) | | — | | (19) | |||||
| Net loss | — | | — | | — | | | — | | (40,798) | | (40,798) | |||||
| Balance as of March 31, 2025 | 95,205,683 | | $9 | | $848,683 | | $401 | | $(419,374) | | $429,719 | ||||||
| Issuance of common stock, net of offering costs | | 9,935,419 | | | 1 | | | 187,100 | | | — | | | — | | | 187,101 |
| Exercise of stock options and vesting of restricted stock | | 151,535 | | | — | | | 233 | | | — | | | — | | 233 | |
| Purchase of common stock under Employee Stock Purchase Plan | | 48,659 | | | — | | | 597 | | | — | | | — | | 597 | |
| Stock-based compensation | | — | | | — | | | 7,733 | | | — | | | — | | 7,733 | |
| Other comprehensive loss | | — | | | — | | | — | | | (197) | | | — | | | (197) |
| Net loss | | — | | | — | | | — | | | — | | | (36,115) | | (36,115) | |
| Balance as of June 30, 2025 | | 105,341,296 | | $10 | | $1,044,346 | | $204 | | $(455,489) | | $589,071 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.